Literature DB >> 18519977

ApoB100 is required for increased VLDL-triglyceride secretion by microsomal triglyceride transfer protein in ob/ob mice.

Zhouji Chen1, Elizabeth P Newberry, Jin Y Norris, Yan Xie, Jianyang Luo, Susan M Kennedy, Nicholas O Davidson.   

Abstract

Microsomal triglyceride transfer protein (Mttp) is a key player in the assembly and secretion of hepatic very low density lipoproteins (VLDL). Here we determined the effects of Mttp overexpression on hepatic triglyceride (TG) and VLDL secretion in leptin-deficient (ob/ob) mice, specifically in relation to apolipoproteinB (apoB) isoforms. We crossed Apobec1(-/-) mice with congenic ob/ob mice to generate apoB100-only ob/ob mice (A-ob/ob). The obesity phenotype in both genotypes was similar, but A-ob/ob mice had greater hepatic TG content. Administration of recombinant adenovirus expressing murine Mttp cDNA (Ad-mMTP) increased hepatic Mttp content and activity and increased hepatic VLDL-TG secretion in A-ob/ob mice. However, despite equivalent overexpression of Mttp, there was no change in VLDL-TG secretion in ob/ob mice in a wild-type Apobec1 background. Metabolic labeling studies in primary hepatocytes from A-ob/ob mice demonstrated that Ad-mMTP increased triglyceride secretion without changing the synthesis and secretion of apoB100, suggesting greater incorporation of TG into existing VLDL particles rather than increased particle number. Ad-mMTP administration failed to increase hepatic VLDL secretion in lean Apobec1(-/-) mice or controls. By contrast, VLDL secretion increased and hepatic TG content decreased following Ad-mMTP administration to human APOB transgenic mice crossed into the Apobec1(-/-) line. These findings demonstrate that Ad-mMTP increases murine hepatic VLDL-TG secretion only in the apoB100 background, and even then only in situations with either increased hepatic TG accumulation or increased apoB100 expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519977      PMCID: PMC2515521          DOI: 10.1194/jlr.M800240-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  36 in total

1.  The inhibition in vivo of lipoprotein lipase (clearing-factor lipase) activity by triton WR-1339.

Authors:  J Borensztajn; M S Rone; T J Kotlar
Journal:  Biochem J       Date:  1976-06-15       Impact factor: 3.857

2.  An inhibitor of the microsomal triglyceride transfer protein inhibits apoB secretion from HepG2 cells.

Authors:  H Jamil; D A Gordon; D C Eustice; C M Brooks; J K Dickson; Y Chen; B Ricci; C H Chu; T W Harrity; C P Ciosek; S A Biller; R E Gregg; J R Wetterau
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

3.  A triglyceride and cholesteryl ester transfer protein associated with liver microsomes.

Authors:  J R Wetterau; D B Zilversmit
Journal:  J Biol Chem       Date:  1984-09-10       Impact factor: 5.157

4.  Triacylglycerol contents and in vivo lipogenesis of ob/ob, db/db and Avy/a mice.

Authors:  T T Yen; J A Allan; P L Yu; M A Acton; D V Pearson
Journal:  Biochim Biophys Acta       Date:  1976-08-23

5.  Changes in the concentration of plasma lipoproteins and apoproteins following the administration of Triton WR 1339 to rats.

Authors:  T Ishikawa; N Fidge
Journal:  J Lipid Res       Date:  1979-02       Impact factor: 5.922

6.  Hepatic VLDL production in ob/ob mice is not stimulated by massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin.

Authors:  Coen H Wiegman; Robert H J Bandsma; Margriet Ouwens; Fjodor H van der Sluijs; Rick Havinga; Theo Boer; Dirk-Jan Reijngoud; Johannes A Romijn; Folkert Kuipers
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

7.  Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes.

Authors:  R V Farese; S L Ruland; L M Flynn; R P Stokowski; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Targeted disruption of the mouse apobec-1 gene abolishes apolipoprotein B mRNA editing and eliminates apolipoprotein B48.

Authors:  K Hirano; S G Young; R V Farese; J Ng; E Sande; C Warburton; L M Powell-Braxton; N O Davidson
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

9.  Conditional intestinal lipotoxicity in Apobec-1-/- Mttp-IKO mice: a survival advantage for mammalian intestinal apolipoprotein B mRNA editing.

Authors:  Yan Xie; Jianyang Luo; Susan Kennedy; Nicholas O Davidson
Journal:  J Biol Chem       Date:  2007-09-12       Impact factor: 5.157

10.  Hepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying allele.

Authors:  Zhouji Chen; Robin L Fitzgerald; Gang Li; Nicholas O Davidson; Gustav Schonfeld
Journal:  J Lipid Res       Date:  2003-09-16       Impact factor: 5.922

View more
  17 in total

Review 1.  Role of xenobiotics in the induction and progression of fatty liver disease.

Authors:  James E Klaunig; Xilin Li; Zemin Wang
Journal:  Toxicol Res (Camb)       Date:  2018-05-18       Impact factor: 3.524

2.  Loss of hepatic PPARα promotes inflammation and serum hyperlipidemia in diet-induced obesity.

Authors:  David E Stec; Darren M Gordon; Jennifer A Hipp; Stephen Hong; Zachary L Mitchell; Natalia R Franco; J Walker Robison; Christopher D Anderson; Donald F Stec; Terry D Hinds
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-09-04       Impact factor: 3.619

Review 3.  Pathway-selective insulin resistance and metabolic disease: the importance of nutrient flux.

Authors:  Yolanda F Otero; John M Stafford; Owen P McGuinness
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

4.  Deficiency in Nrf2 transcription factor decreases adipose tissue mass and hepatic lipid accumulation in leptin-deficient mice.

Authors:  Jialin Xu; Ajay C Donepudi; Vijay R More; Supriya R Kulkarni; Liya Li; Liangran Guo; Bingfang Yan; Tapan Chatterjee; Neal Weintraub; Angela L Slitt
Journal:  Obesity (Silver Spring)       Date:  2014-11-29       Impact factor: 5.002

5.  Central effects of humanin on hepatic triglyceride secretion.

Authors:  Zhenwei Gong; Kai Su; Lingguang Cui; Emir Tas; Ting Zhang; H Henry Dong; Shoshana Yakar; Radhika H Muzumdar
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-06-09       Impact factor: 4.310

6.  Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha) stimulates VLDL assembly through activation of cell death-inducing DFFA-like effector B (CideB).

Authors:  Zhouji Chen; Jin Y Norris; Brian N Finck
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

7.  IRE1α-XBP1s induces PDI expression to increase MTP activity for hepatic VLDL assembly and lipid homeostasis.

Authors:  Shiyu Wang; Zhouji Chen; Vivian Lam; Jaeseok Han; Justin Hassler; Brian N Finck; Nicholas O Davidson; Randal J Kaufman
Journal:  Cell Metab       Date:  2012-10-03       Impact factor: 27.287

8.  Pathogenesis and Prevention of Hepatic Steatosis.

Authors:  Fatiha Nassir; R Scott Rector; Ghassan M Hammoud; Jamal A Ibdah
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-03

9.  Allele-specific regulation of MTTP expression influences the risk of ischemic heart disease.

Authors:  Anna Aminoff; Helena Ledmyr; Petra Thulin; Kerstin Lundell; Leyla Nunez; Elisabeth Strandhagen; Charlotte Murphy; Ulf Lidberg; Jukka Westerbacka; Anders Franco-Cereceda; Jan Liska; Lars Bo Nielsen; Mats Gåfvels; Maria Nastase Mannila; Anders Hamsten; Hannele Yki-Järvinen; Dag Thelle; Per Eriksson; Jan Borén; Ewa Ehrenborg
Journal:  J Lipid Res       Date:  2010-01       Impact factor: 5.922

10.  Protein kinase STK25 controls lipid partitioning in hepatocytes and correlates with liver fat content in humans.

Authors:  Manoj Amrutkar; Matthias Kern; Esther Nuñez-Durán; Marcus Ståhlman; Emmelie Cansby; Urszula Chursa; Elin Stenfeldt; Jan Borén; Matthias Blüher; Margit Mahlapuu
Journal:  Diabetologia       Date:  2015-11-09       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.